Patent Application
20070112077
This invention relates to analogs of vitamin D compounds that do not include the C and D rings, more particularly to des-C, D analogs of 1α,25-dihydroxy-19-norvitamin D3, and still more particularly to des-C, D analogs of 2-methylene-1α,25-dihydroxy-19-norvitamin D3 and to pharmaceutical formulations that include these compounds or mixtures thereof. The invention also relates to the use of the compounds, and mixtures thereof in the preparation of medicaments for use in treating various diseases.
The natural hormone, 1α,25-dihydroxyvitamin D3 (also referred to as 1α,25-dihydroxycholecalciferol and calcitriol) and its analog in the ergosterol series, i.e. 1α,25-dihydroxyvitamin D2 are known to be highly potent regulators of calcium homeostasis in animals and humans, and their activity in cellular differentiation has also been established, Ostrem et al., Proc. Natl. Acad. Sci. USA, 84, 2610 (1987). Many structural analogs of these metabolites have been prepared and tested, including 1α-hydroxyvitamin D3, 1α-hydroxyvitamin D2, various side chain homologated vitamins, and fluorinated analogs. Some of these compounds exhibit an interesting separation of activities in cell differentiation and calcium regulation. This difference in activity may be useful in the treatment of a variety of diseases as renal osteodystrophy, vitamin D-resistant rickets, osteoporosis, psoriasis, and certain malignancies. The structure of 1α,25-dihydroxyvitamin D3 and the numbering system used to denote the carbon atoms in this compound are shown below.
Another class of vitamin D analogs, i.e. the so called 19-nor-vitamin D compounds, is characterized by the replacement of the A-ring exocyclic methylene group (carbon 19), typical of the vitamin D system, by two hydrogen atoms. Biological testing of such 19-nor-analogs (e.g., 1α,25-dihydroxy-19-nor-vitamin D3) revealed a selective activity profile with high potency in inducing cellular differentiation, and very low calcium mobilizing activity. Thus, these compounds are potentially useful as therapeutic agents for the treatment of malignancies, or the treatment of various skin disorders. Two different methods of synthesis of such 19-nor-vitamin D analogs have been described (Perlman et al., Tetrahedron Lett. 31, 1823 (1990); Perlman et al., Tetrahedron Lett. 32, 7663 (1991), and DeLuca et al., U.S. Pat. No. 5,086,191).
Various 2-substituted analogs of 1α,25-dihydroxy-19-nor-vitamin D3 have also been synthesized, i.e. compounds substituted at the 2-position with hydroxy or alkoxy groups (DeLuca et al., U.S. Pat. No. 5,536,713), with 2-alkyl groups (DeLuca et a., U.S. Patent No. 5,945,410), and with 2-alkylidene groups (DeLuca et al., U.S. Pat. No. 5,843,928), which exhibit interesting and selective activity profiles. All these studies indicate that binding sites in vitamin D receptors can accommodate different substituents at C-2 in the synthesized vitamin D analogs.
U.S. Pat. No. 4,666,634 discloses 2p-hydroxy and alkoxy (e.g., ED-71) analogs of 1α,25-dihydroxyvitamin D3 as potential drugs for use in treating osteoporosis and for use as antitumor agents. See also Okano et al., Biochem. Biophys. Res. Commun. 163, 1444 (1989). Other 2-substituted (with hydroxyalkyl, e.g., ED-120, and fluoroalkyl groups) A-ring analogs of 1α,25-dihydroxyvitamin D3 have been prepared and tested (Miyamoto et al., Chem. Pharm. Bull. 41, 1111 (1993); Nishii et al., Osteoporosis Int Suppl. 1, 190 (1993); Posner et aL, J. Org. Chem. 59, 7855 (1994), and J. Org. Chem. 60, 4617 (1995)).
In a continuing effort to explore the 19-nor class of pharmacologically important vitamin D compounds, their analogs which are characterized by the transposition of the ring A exocyclic methylene group from carbon 10 (C-10) to carbon 2 (C-2), i.e. 2-methylene-19-nor-vitamin D compounds have been recently synthesized and tested (Sicinski etal., J. Med. Chem., 41, 4662 (1998); Sicinski et al., Steroids 67, 247 (2002); DeLuca etal., U.S. Pat. Nos. 5,843,928, 5,936,133 and 6,382,071). Molecular mechanics studies, performed on these analogs, showed that a change of ring-A conformation can be expected resulting in the “flattening” of the cyclohexanediol ring. From molecular mechanics calculations and NMR studies of these compounds, the A-ring conformational equilibrium was established to be about 6:4 in favor of the conformer that has an equatorial 1 α-OH. Introduction of the 2-methylene group into the 19-nor-vitamin D carbon skeleton changes the character of its (1α- and 3β-) A-ring hydroxyl groups; they are both now in the allylic positions, similar to the 1 a-hydroxyl group (important for biological activity) in the natural hormone, 1α,25-(OH)2D3. 1 α,25-Dihydroxy-2-methylene-19-norvitamin D analogs are characterized by significant biological potency which is enhanced in compounds with the “unnatural” (20S)-configuration.
In a continuing effort to explore the 19-nor class of pharmacologically important vitamin D compounds, analogs which are characterized by the presence of a methylene substituent at carbon 2 (C-2), a hydroxyl group at carbon 1 (C-1), and a shortened side chain attached to carbon 20 (C-20) have also been synthesized and tested. 1α-Hydroxy-2-methylene-19-nor-pregnacalciferol is described in U.S. Pat. No. 6,566,352 while 1α-hydroxy-2-methylene-19-nor-(20S)-homopregnacalciferol is described in U.S. Pat. No. 6,579,861 and 1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is described in U.S. Pat. No. 6,627,622. All three of these compounds have relatively high binding activity to the vitamin D receptor and relatively high cell differentiation activity, but little if any calcemic activity as compared to 1α,25-dihydroxyvitamin D3. Their biological activities make these compounds excellent candidates for a variety of pharmaceutical uses, as set forth in the '352 , '861 and '622 patents.
An interesting modification of the vitamin D skeleton is removal of its C and D rings. The first compound (retiferol) lacking the C,D-substructure was disclosed by Kutner et al. ten years ago (Kutner et al., Bioorg. Chem., 23, 22 (1995). Several other des-C,D vitamin D3 derivatives, including 19-nor analogs, have been disclosed (Bauer et al., U.S. Pat. No. 5,969,190; Barbier et al., U.S. Pat. No. 6,184,422) and some of them (Ro 65-2299) have been reported to show improved biological activities [Hilpert and Wirz, Tetrahedron, 57, 681 (2001)].
The invention provides compounds that are analogs of 1α,25-dihydroxy-19-norvitamin D3 that lack the C and D rings such as des-C,D analogs of 2-methylene-19-norvitamin D3, pharmaceutical formulations that include the compounds, and the use of these compounds or mixtures thereof in the preparation of medicaments for use in treating various disease states.
Therefore, in one aspect, the invention provides a 2-methylene-19-norvitamin D3 analog that lacks the C and D rings. In some embodiments, the invention provides compounds of formula 1 having the structure shown below:
wherein
In some embodiments, the invention provides compounds having the formula 1A, formula 1B, formula 1C, or a mixture thereof as shown below:
wherein,
In some embodiments, Y1 and y2 are both hydroxy protecting groups such as silyl groups. In some such embodiments, Y1 and y2 are both t-butyldimethylsilyl groups. In some embodiments, y3 is a trialkylsilyl group such as a trimethylsilyl or trimethylsilyl group. In other embodiments, y1, y2, and y3 are all H such that the compound has the formula 1A1, 1B1, or 1C1 as shown below. In some such embodiments, each of X1, X2, X3, and X4 is independently selected from H or a methyl group.
In some embodiments, the compounds of formula 1A, 1B, and 1C have the formula 1A2, 1B2, or 1C2 as shown below:
wherein,
In some such embodiments, each of y1,y2, and y3is H. In some embodiments each of X1, X2, X3, and X4 is independently selected from H or a methyl group.
In some embodiments, the invention provides compounds of formula 1C having the formula 1C3 as shown below:
wherein y1, y2, and y3 are independently selected from H or hydroxy-protecting groups. In some such embodiments, y1, y2, and y3 are all hydroxy protecting groups such as silyl groups. In some such embodiments, y1, and y2 are t-butyidimethylsilyl groups and y3 is a trialkylsilyl group such as a triethylsilyl group. In other embodiments, y1, y2, and y3 are all H such that the compound has the formula 1 C4 as shown below:
In some embodiments, the compounds of any of the embodiments may be present in a purified form. In other embodiments, the compounds in a composition may be present as a mixture. In some embodiments, the mixture includes a first compound of the invention and a second compound of the invention, and the ratio of the first compound to the second compound ranges from 50:50 to 99.9:0.1. In some such embodiments, the ratio of the first compound to the second compound ranges from 70:30 to 99.9:0.1, from 80:20 to 99.9:0.1, from 90:10 to 99.9:0.1, or from 95:5 to 99.9:0.1.
The above compounds were/are tested and found to exhibit desired, and highly advantageous, patterns of biological activity with respect to intestinal calcium transport activity, ability to mobilize calcium from bone, and ability to bind to the vitamin D receptor. The compounds may thus find use in treating cancer, skin conditions, and autoimmune disorders. Therefore, in some embodiments, these compounds or pharmaceutical formulations that include one or more compounds of the invention may be employed as therapeutic agents for the treatment of diseases or disorders such as cancer, autoimmune diseases, skin conditions, and secondary hyperparathyroidism. In some embodiments, the treatment may be transdermal, oral, or parenteral.
The compounds of the invention may also be especially suited for treatment and prophylaxis of human disorders which are characterized by an imbalance in the immune system, e.g., in autoimmune diseases, including multiple sclerosis, diabetes mellitus, host versus graft reaction, and rejection of transplants; and additionally, for the treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, as well as the improvement of bone fracture healing and improved bone grafts. Acne, alopecia, skin conditions such as dry skin (lack of dermal hydration), undue skin slackness (insufficient skin firmness), insufficient sebum secretion and wrinkles, and hypertension are other conditions which may be treated with the compounds of the invention.
The compounds described herein were also tested and found to moderate cell differentiation activity. Thus, these compounds may also be used as therapeutic agents for the treatment of psoriasis and/or as anti-cancer agents, especially against leukemia, colon cancer, breast cancer and prostate cancer. In some embodiments, the compounds and compositions of the invention are used to treat a biological condition selected from psoriasis; leukemia; colon cancer; breast cancer; prostate cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, eczema, or inflammatory bowel diseases; a skin condition selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion; or secondary hyperparathyroidism.
In some embodiments of the methods of the invention, the compound or pharmaceutical composition is administered orally, rectally, parenterally, transdermally, or topically. In other embodiments, the compound or pharmaceutical formulations is administered in an aerosol which may be accomplished using an inhaler or a nebulizer.
The compounds of the invention may be used to prepare pharmaceutical formulations or medicaments that include a compound or a mixture of the compounds of the invention in combination with a pharmaceutically acceptable carrier. Such pharmaceutical formulations and medicaments may be used to treat various biological disorders such as those described herein. Methods for treating such disorders typically include administering an effective amount of the compound, or an appropriate amount of a pharmaceutical formulation or a medicament that includes the compound, to a subject suffering from the biological disorder. “Subject,” as used herein, refers to any animal that may experience the beneficial effects of a compound of the invention upon administration of the compound to the animal. In some embodiments, the subject is a mammal. In some such embodiments, the mammal is selected from a rodent, a primate, a bovine, an equine, a canine, a feline, an ursine, a porcine, a rabbit, or a guinea pig. In some such embodiments, the mammal is a rat or is a mouse. In some embodiments, the subject is a primate such as, in some embodiments, a human. In some embodiments, the compounds are used to prepare an aerosol which may include a glycol compound such as propylene glycol.
The compounds may be present in a composition to treat the above-noted diseases and disorders in an amount from about 0.01 μg/gm to about 1 mg/gm of the composition, preferably from about 0.1 μg/gm to about 500 μg/gm of the composition, and may be administered topically, transdermally, orally, rectally, or parenterally in dosages of from about 0.01 μg/day to about 1 mg/day, preferably from about 0.1 μg/day to about 500 μg/day.
Further objects, features and advantages of the invention will be apparent from the following detailed description.
Generally, the invention provides compounds that are analogs of 1α,25-dihydroxy-19-norvitamin D3 that lack the C and D rings (des-C,D compounds) such as des-C,D analogs of 2-methylene-1α,25-dihydroxy-19-norvitamin D3, pharmaceutical formulations that include the compounds, and the use of these compounds or mixtures thereof in the preparation of medicaments for use in treating various disease states.
In one aspect, the invention provides a 2-methylene-19-norvitamin D3 analog that lacks the C and D rings (a des-C,D-2-methylene-19-norvitamin D3 analog) such as des-C,D-2-methylene-1α,25-dihydroxy-19-norvitamin D3. By 2-methylene-19-norvitamin D3 analog is meant a compound that is an agonist of the vitamin D receptor and at least comprises the 2-methylene-19-norvitamin D3A ring. In some embodiments, the invention provides compounds of formula 1 having the structure shown below:
wherein,
In some embodiments of the compound of formula 1, R1 is a straight or branched chain alkyl or alkylene group having from 8 to 20 carbons and bearing an OY3 group. In some such embodiments, the alkyl or alkylene group has 8 to 11, 8 to 12 or 8 to 15 carbons.
In some embodiments, the invention provides compounds having the formula 1A, formula 1B, formula 1C, or a mixture thereof as shown below:
wherein,
As used herein, the phrase “straight and branched chain alkyl groups” refers to groups that include carbon and hydrogen atoms that only include carbon-carbon single bonds and carbon-hydrogen single bonds. Thus, the phrase “straight and branched chain alkyl groups” having 1 to 4 carbon atoms includes alkyl groups such as methyl, ethyl, propyl, i-propyl, and butyl groups.
As used herein, the term “hydroxy-protecting group” signifies any group commonly used for the temporary protection of the hydroxy (-OH) functional group, such as, but not limited to, alkoxycarbonyl, acyl, alkylsilyl or alkylarylsilyl groups (hereinafter referred to simply as “silyl” groups), and alkoxyalkyl groups. Alkoxycarbonyl protecting groups are alkyl-O-CO- groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl or allyloxycarbonyl. The term “acyl” signifies an alkanoyl group of 1 to 6 carbons, in all of its isomeric forms, or a carboxyalkanoyl group of 1 to 6 carbons, such as an oxalyl, malonyl, succinyl, glutaryl group, or an aromatic acyl group such as benzoyl, or a halo, nitro or alkyl substituted benzoyl group. Alkoxyalkyl protecting groups are groups such as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, or tetrahydrofuranyl and tetrahydropyranyl. Preferred silyl-protecting groups are trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, dibutylmethylsilyl, diphenylmethylsilyl, phenyidimethylsilyl, diphenyl-t-butylsilyl and analogous alkylated silyl radicals. The term “aryl” specifies a phenyl-, or an alkyl-, nitro- or halo-substituted phenyl group. An extensive list of protecting groups for the hydroxy functionality may be found in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999) which can be added or removed using the procedures set forth therein and which is hereby incorporated by reference in its entirety and for all purposes as if fully set forth herein.
A “protected hydroxy” group is a hydroxy group derivatized or protected by any of the above groups commonly used for the temporary or permanent protection of hydroxy functional groups, e.g., the silyl, alkoxyalkyl, acyl or alkoxycarbonyl groups, as previously defined.
The preparation of des-C,D-19-nor-vitamin D compounds of formula 1A, 1B, and 1C can be accomplished using either of two general methods. In the first method, the Wittig-Horner coupling of an aldehyde (IIa or IIb) with an allylic phosphine oxide (III) is employed. In an alternative procedure, Julia olefination is performed and includes coupling of an unsaturated sulfone (IVa or IVb), easily prepared from the aldehydes IIa or IIb, with the cyclohexanone derivative V. Compounds IIA, IIB, III, IVa, IVb, and V are shown below where the variables have the same meanings as defined above with respect to the compounds of formula 1A, 1B, and 1C, and the wavy lines indicate that both cis and trans isomers are represented in formula IIA and IVA:
In the structures shown above, Ar represents an aromatic group such as a phenyl, a substituted phenyl, a 2-phenyltetrazolyl, a 2-benzothiazolyl group, and other aromatic groups that are suitable for the Julia olefination process. Those skilled in the art will recognize that any functionalities in the Ar group that might be sensitive to, or interfere with, the condensation reaction, should be avoided. In phosphine oxide III, and cyclohexanone V, Y1. and Y2 are preferably hydroxy-protecting groups such as silyl protecting groups. The t-butyidimethylsilyl (TBDMS) group is an example of a particularly useful hydroxy-protecting group. The general procedures described above represent an application of the convergent synthesis concept, which has been applied effectively for the preparation of vitamin D compounds (e.g. Kittaka et al, Synlett, 8, 1175 (2003), and J. Org. Chem., 68, 7407 (2003).
Phosphine oxide III and cyclohexanone V are convenient reagents that can be used to prepare a large number of 19-nor vitamin D compounds including des-C,D analogs. These compounds may be prepared according to the procedures described by Sicinski et al., J. Med. Chem., 41, 4662 (1998), DeLuca et al., U.S. Pat. No. 5,843,928; Perlman etal., Tetrahedron Left. 32, 7663 (1991); and DeLuca etal., U.S. Pat. No. 5,086,191. Scheme 1 shows the general procedure for synthesizing phosphine oxide III (See Scheme 1, compound H) and cyclohexanone V (See Scheme 1, compound D) as outlined in U.S. Pat. No. 5,843,928 which is hereby incorporated by reference in its entirety as if fully set forth herein. Modification of the method shown in Scheme 1 may be used to produce a large number of vitamin D analogs as will be apparent to those skilled in the art. For example, a wide variety of phosphonium compounds may be used in place of the MePh3P+Br− used to convert ketone B to alkene C. Examples of such compounds include EtPh3P+Br−, PrPh3P+Br−, and compounds generally prepared by reaction of triphenylphosphine with an alkyl halide, an alkenyl halide, a protected-hydroxyalkyl halide, and a protected hydroxyalkenyl halide. Alkenes prepared using this procedure may then be carried through to prepare a phosphine oxide in an analogous manner to that used to prepare phosphine oxide H in Scheme 1. Alternatively, an alkene analogous to compound C of Scheme 1 may be reduced with (Ph3P)3RhCl and H2 to provide other vitamin D analogs. See U.S. Patent No. 5,945,410 and Sicinski, R. R. etal., J. Med. Chem., 41, 4662-4674 (1998) both of which are hereby incorporated by reference in their entireties and for all purposes. Therefore, the procedure for forming the phosphine oxide shown in Scheme 1 may be used to prepare a wide variety of vitamin D analogs in addition to the compounds of the present invention.
Reference should be made to the following description as well as to Schemes 1, 2, and 3 for a detailed illustration of the preparation of compounds of formula 1A, 1B, and 1C and specifically 2-methylene-1α,25-dihydroxy-des-C,D-19-norvitamin D3.
The synthesis and characteristics of various 19-nor vitamin D analogs is described in numerous United States patents including U.S. Pat. Nos.5,843,928, 6,627,622, 6,579,861, 5,086,191, 5,585,369, and 6,537,981. Each of the above-described references is hereby incorporated by reference in its entirety and for all purposes as if fully set forth herein.
Melting points (uncorrected) were determined using a Thomas-Hoover capillary melting-point apparatus. Ultraviolet (UV) absorption spectra were recorded with a Perkin-Elmer Lambda 3B UV-VIS spectrophotometer in ethanol. 1H nuclear magnetic resonance (NMR) spectra were recorded at 400 and 500 MHz using Bruker Instruments DMX-400 and DMX-500 Avance console spectrometers in CDCl3. 13C nuclear magnetic resonance (NMR) spectra were recorded at 125 MHz with a Bruker Instruments DMX-500 Avance console spectrometer in CDCl3. Chemical shifts (δ) are reported downfield from internal Me4Si (δ0.00). Electron impact (El) mass spectra were obtained with a Micromass AutoSpec (Beverly, Mass.) instrument. High-performance liquid chromatography (HPLC) was performed on a Waters Associates liquid chromatograph equipped with a Model 6000A solvent delivery system, a Model U6K Universal injector, and a Model 486 tunable absorbance detector. THF was freshly distilled before use from sodium benzophenone ketyl under argon.
Schemes 1, 2, and 3 outline the synthetic procedures described below, in detail.
A. Protection of 3-Hydroxy Group of Ester 1 (Scheme 2)
To a solution of R-(−)-methyl-3-hydroxy-2-methylpropionate 1 (4 mL, 4.26 g, 0.036 mol) in anhydrous CH2Cl2 (30 mL) was added N,N-diisopropylethylamine (11.8 mL, 8.75 g, 0.06 mol) at room temperature. The mixture was cooled to −78° C. and benzyl chloromethyl ether (5.6 mL, 6.29 g, 0.04 mol) was added dropwise via cannula. The cooling bath was removed, and the reaction mixture was stirred at room temperature for 16 hours. Tetrabutylammonium iodide (50 mg) and benzyl chloromethyl ether (2 mL, 3.15 g, 0.02 mol) were then added to the reaction mixture. The mixture was stirred at room temperature for 3 hours, poured into water, and extracted with methylene chloride. The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was chromatographed on silica gel using hexane/EtOAc (9:1) as an eluent to give product 2 (8.29 g, 97%) as a colorless oil.
2: [α]24D −3° (c 0.17, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.19 (3H, d, J=7.1 Hz, CH—CH3), 2.77 (1H, m, CH—CH3), 3.64 (1H, dd, J=9.4, 5.4 Hz, one of CH2—CH), 3.70 (3H, s, CH30), 3.78 (1H, dd, J=9.4, 7.8 Hz, one of CH2 —CH), 4.57 (2H, s, OCH2O), 4.74 (2H, s, CH2Ph), 7.29 (1H, m, Ar—Hpara), 7.35 (4H, m, Ar—Hortho,meta); 13C NMR (125 MHz) δ13.91 (CH3), 39.99 (CH—CH3), 51.70 (CH3O), 69.22 and 69.60 (CH2CH and CH2—Ph), 94.50 (OCH2O), 127.63, 127.84 and 128.33 (Arortho,meta,para), 137.61 (Aripro); MS (El) m/z (relative intensity) no M+, 207(M+−OCH3, 2), 131 (34), 120 (64), 91 (100); HRMS (ESI) exact mass calculated for C13H18O4 Na (M++Na) 261.1103, measured 261.1110.
B. Reduction of Ester 2
A solution of ester 2 (0.5 g, 2.1 mmol) in anhydrous THF (4 mL) was added dropwise to a suspension of lithium aluminum hydride (0.16 g, 4.2 mmol) in anhydrous THF (10 mL) at 0° C. The cooling bath was removed, and the reaction was stirred at room temperature overnight, quenched with cold water, and extracted with EtOAc. The solvents were removed in vacuum and the crude oil was purified by silica gel chromatography using hexane/EtOAc (8:2) as an eluent to afford oily diol 3 (0.29 g, 66%).
3: [α]24D−3° (c 0.17, CHCl3); ); 1H NMR (500 MHz, CDCl3) δ0.92 (3H, d, J=7.1 Hz, CH—CH3), 2.02 (1H, m, CH—CH3), 2.39 (1H, s, OH), 3.54 (1H, dd, J=9.4, 7.6 Hz, one of CH2—CH), 3.60 (d, J=9.4 Hz, CH2OH), 3.65 (1H, dd, J=9.4, 4.8 Hz, one of CH2—CH), 4.6 (2H, s, OCH2O), 4.75 (2H, s, CH2Ph), 7.30 (1H, m, Ar—Hpara), 7.35 (4H, d, J=4.3 Hz, Ar—Hortho,meta); 13C NMR (125 MHz) δ13.61 (CH3), 35.62 (CH—CH3), 67.19 (CH2OH), 69.58 (CH2CH), 72.38 (CH2—Ph), 94.79 (OCH2O) 127.82, 127.90 and 128.49 (Arortho,meta,para), 137.58 (Aripso); MS (El) m/z (relative intensity) no M+, 180 (8), 120(100), 108 (95), 89 (72); HRMS (ESI) exact mass calculated for C12H,18O3Na (M++Na) 233.1154, measured 233.1158.
C. Tosylation of Hydroxy Compound 3
To a mixture of diol 3 (29.2 mmol, 6.13 g), DMAP (0.82 mmol, 100 mg) and triethylamine (116.7 mmol, 16.2 mL, 11.8 g) in anhydrous CH2Cl2 (60 mL) was added tosyl chloride (37.9 mmol, 7.23 g) at 0° C. The reaction mixture was allowed to warm to room temperature and stirring was continued overnight. The mixture was then diluted with CH2Cl2 (100 mL) and was then washed with a saturated aqueous solution of NaHCO3, dried over Na2SO4, and concentrated under reduced pressure. The residue was chromatographed on a silica gel using hexane/EtOAc (7:3) as an eluent to give the oily tosylate 4 (10.2 g, 97%).
4: [α]24D −5° (c 0.15, CHCl3); 1H NMR (500 Hz, CDCl3) δ0.94 (3H, d, j =7.1 Hz, CH—CH3), 2.09 (1H, m, CH—CH3), 2.42 (3H, s, CH3Ph), 3.42 (1H, dd, J=9.4, 6.6 Hz, one of CH2—CH), 3.47 (1H, dd, J=9.4, 5.1 Hz, one of CH2—CH), 3.97 (1H, dd, J=9.4, 5.8 Hz, one of CH2—OTs), 4.03 (1H, dd, J=9.4, 5.8 Hz, one of CH2—OTs), 4.51 (2H, s, OCH2O), 4.65 (2H, s, CH2Ph), 7.30 (7H, br m, Ar—H), 7.78 (2H, J=8.2 Hz, Ar—Horthofrom tosyl); 13C NMR (125 MHz) δ13.58 (CH3), 21.60 (Ph—CH3), 33.45 (CH—CH3), 68.61 (CH2CH), 69.27 (CH2OTs), 71.96 (CH2—Ph), 94.56 (OCH2O), 127.68, 127.82, 128.36, 129.75, 132.6, 137.58 and 144.66 (Ar); MS (El) m/z (relative intensity) no M+, 257(M+−OCH2Ph, 65), 245 (55), 227 (81), 86 (100); HRMS (ESI) exact mass calculated for C19H24O5SNa (M++Na) 387.1242, measured 387.1252.
D. Reaction of Tosylate 4 with Grignard Reagent
-Chloro-2-methyl-2-butane (15.5 mL, 14.4 g, 137.5 mmol) was added dropwise to stirred magnesium turnings (6.75 g, 225 mmol) in anhydrous THF (465 mL) under argon at 0° C. The stirring was continued 0° C. for 1 hour. The cooling bath was removed, and the mixture was stirred at room temperature for an additional 1.5 hours. The mixture was then cooled to −78° C. and the formed Grignard reagent was added via cannula to a solution of tosylate 4 (10 g, 27.5 mmol) in anhydrous THF (70 mL). Li2CuCl4 (160mL) [previously prepared from LiCl (1.36 g, 32.1 mmol) and CUCl2 (2.17 g, 16.1 mmol)] was then added to the reaction mixture. The cooling bath was removed, and the reaction was stirred at room temperature for 17 hours. The mixture was extracted with CH2Cl2, and the organic layer was washed with NH4Cl and NaHCO3, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel using hexane/EtOAc (7:3) as an eluent to give oily product 5 (5.65 g, 78%).
5: [α]24D +2° (c 0.24, CHCl3); 1H NMR (400 Hz, CDCl3) δ0.94 (3H, d, j =6.6 Hz, CH—CH3), 1.18 and 1.46 (1H and 1H, each m), 1.60 and 1.68 [3H and 3H, each s, ═C(CH3)2], 1.87 (1H, m, CH—CH3), 2.05 (2H, m, ═CCH2), 3.37 (1 H, dd, j=9.4, 6.8 Hz, one of CH2—CH), 3.44 (1H, dd, J=9.4, 5.8 Hz, one of CH—CH), 4.60 (2H, s, OCH2O), 4.76 (2H, s, CH2Ph), 5.10 (1H, br t, J ˜7 Hz, CH=C), 7.30 (1H, m, Ar—Hpara), 7.34 (4H, m, Ar-Hortho,meta); 13C NMR (125 MHz) δ16.96 (CH—CH3), 17.53 (one of CH3C═), 25.60 (one of CH3C═), 32.92 (CH—CH3), 33.57 (CH2CH2CH), 69.27 (CH2-Ph), 73.37 (CH2CH), 94.64 (OCH2O), 124.49 (C—CH3), 127.52, 127.77, 128.28, (Arorho,meta,para), 137.95 [═C(CH3)2]; MS (El) m/z (relative intensity) 262 (M+, 22), 232.2 (65), 154.1 (100); HRMS (ESI) exact mass calculated for C17H26O2Na (M++Na) 285.1830, measured 285.1837.
E. Epoxidation of Olefin 5
Olefin 5 (3.2 g, 12.2 mmol) was dissolved in anhydrous CH2Cl2 (60 mL), and NaHCO3 (1.6 g, 18.4 mmol) was added. Then, 3-chloroperoxybenzoic acid (60%, 12.8 g, 36.6 mmol) was added at room temperature with stirring. The stirring was continued for 24 hours, and the mixture was diluted with ether, and shaken with water and 2M NaOH. The organic layer was washed with water and saturated NH4Cl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel using hexane/EtOAc (9:1) as an eluent to give the oily product 6 (2.5 g, 74%).
6: [α]24D −1.7° (c 0.88, CHCl3); 1H NMR (500 Hz, CDCl3) δ0.96 (3H, d, J=6.7 Hz, CH—CH3), 1.25 (1H, m), 1.27 and 1.31 [3H and 3H, each s, C (CH3)2], 1.5-1.7 (3H, br m), 1.79 (1H, m, CH—CH3), 2.73 (1H, m, CH2CHO), 3.45 (2H, br m, CH2—CH), 4.60 (2H, s, OCH2O), 4.76 (2H, s, CH2Ph), 7.29 (1H, m, Ar—Hpara), 7.34 (4H, d, j =4.3 Hz, Ar—Hortho,meta).
F. Reduction of Epoxide 6
To a solution of the epoxide 6 (2.5 g, 9 mmol) in anhydrous ether (75 mL) at 0° C. was added lithium aluminum hydride (1.7 g, 67.5 mmol). The cooling bath was removed and the reaction was stirred at room temperature overnight. The reaction was then quenched with cold water and aqueous NH4Cl, and extracted with CH2Cl2. The solvents were removed under reduced pressure and the crude oil was chromatographed on a silica gel using hexane/EtOAc (9:1) as an eluent to give an oily alcohol 7 (2 g, 80%).
7: [α]24D −4° (c 0.19, CHCl3); 1H NMR (200 Hz, CDCl3) δ0.94 (3H, d, j =6.5 Hz, CH—CH3), 1.20 [6H, s, (CH3)2COH], 1.75 (1H, m, CH—CH3), 3.38 (1H, d, j =10.8, 6.6 Hz, one of CH2—CH), 3.46 (1H, dd, J=10.8, 6.0 Hz, one of CH2—CH), 4.60 (2H, s, OCH2O), 4.76 (2H, s, CH2Ph), ca. 7.3 (5H, m, Ar—H); HRMS (ESI) exact mass calculated for C17H28O3Na (M++Na) 303.1936, measured 303.1947.
G. Removal of BOM Protecting Group
To a solution of an alcohol 7 (1.8 g, 0.01 mol) in ethyl acetate (20 mL) was added Pd/C (10%, 100 mg) at room temperature. The reaction mixture was stirred for 5 days and Pd/C (150 mg) was added 3 times per day. The reaction was then filtered, and the solvent was evaporated under reduced pressure. The crude oil was chromatographed on silica gel using hexane/EtOAc (1:1) as an eluent to give an oily diol 8 (0.95 g, 92%).
8: [α]24D +11° (c 1.28, CHCl3); 1H NMR (200 Hz, CDCl3) δ0.93 (3H, d, j =6.6 Hz, CH—CH3), 1.20 [6H, s, (CH3)2COH], 1.65 (1H, m, CH—CH3), 3.45 (2H, br m, CH2—CH); 13C NMR (50 MHz) δ16.63 (CH—CH3), 21.64 (CH2—CH2—CH2), 29.19 [C(CH3)], 29.29 [C(CH3)], 33.62 (CH—CH2—CH2), 35.68 (CH—CH3), 44.03 (CH2COH), 68.19 (CH2OH), 71.16 [C(CH3)2]; MS (ES) 183 (M++Na); HRMS (ESI) exact mass calculated for C9H20O2Na (M++Na) 183.1361, measured 183.1351.
H. Oxidation of Diol 8
Pyridinium dichromate (1.5 g, 3.75 mmol) was added to a stirred solution of diol 8 (110 mg, 0.69 mmol) and pyridinium p-toluenesulfonate (33 mg, 0.11 mmol) in CH2Cl2 (5 mL). The resulting suspension was stirred for 4 hours at room temperature under argon. The reaction was then filtered through Celite and solvent was evaporated under reduced pressure. The residue was chromatographed on silica gel using hexane/EtOAc (9:1) as an eluent to give an oily aldehyde 9 (65 mg, 60%).
9: [α]24D −10.5° (c 1.1, CHCl3); 1H NMR (400 Hz, CDCl3) δ1.06 (3H, d, j =7.0 Hz, CH—CH3), 1.21 [6H, s, (CH3)2COH], 2.37 (1H, m, CH—CH3), 9.62 (1 H, d, j=1.9 Hz, CHO); 13C NMR (25 MHz) δ13.33 (CH—CH3), 21.70 (CH2—CH2—CH2), 29.21 [C(CH3)2], 30.89 (CH—CH2), 43.70 (CH2COH), 46.30 (CHCH3), 71.16 [C(CH3) 2], 205.25 (CHO).
I. Silylation of Hydroxy Aldehyde 9
To a solution of aldehyde 9 (93.4 mg, 0.6 mmol) and 2,6-lutidine (170 μL, 1.5 mmol) in anhydrous CH2Cl2 (3.7 mL) was added dropwise Et3SiOTf (161 μL, 0.72 mmol) at 0° C. under argon. The solution was stirred at 10° C. for 3 hours and then at room temperature for 30 minutes. The mixture was quenched with cold water and extracted with CH2Cl2. The solvent was removed under reduced pressure, and the residue was chromatographed on silica Sep-Pak cartridge using hexane/EtOAc (99.7:0.3) as an eluent to give an oily aldehyde 10 (130 mg, 81%).
10: [α]24D +4.2° (c 1.75, CHCl3); 1 H NMR (500 Hz, CDCl3) δ0.56 (6H, q, J=7.8 Hz, 3 ×SiCH2), 0.94 (9H, t, J=7.8 Hz, 3 ×SiCH2CH3), 1.10 (3H, d, j =6.8 Hz, CH—CH3), 1.19 [6H, s, (CH3)2CO], 2.37 (1H, d sext, J=1.9, 6.8 Hz, CH—CHO), 9.62 (1H, d, J=1.95 Hz, CHO).
J. Wittig Reaction of Aledhyde 10
To a solution of a phosphonium bromide 11 (275 mg, 0.54 mmol) in anhydrous THF (12 mL) was added dropwise n-BuLi (2 M in cyclohexane, 270 μL, 0.54 mmol) at −20° C. After 15 minutes of stirring at −20° C., the reaction was cooled to −50° C. and ⅔ of the orange solution of the formed Wittig reagent was added via cannula to the stirred solution of aldehyde 10 (50 mg, 0.18 mmol) in anhydrous THF (2 mL). After 1 hour of stirring at −50° C., brine and 1 M HCI were added, and the mixture was extracted with EtOAc. The organic layer was washed with water and evaporated. The residue was chromatographed on silica Sep-Pak cartridge eluted with hexane/EtOAc (98.5:1.5) to give an oily compound 12 (59.3 mg, 75%).
12: [α]24D −5.5° (c 0.48, CHCl3); 1H NMR (500 Hz, CDCl3) δ0.058(6H, s, 2 ×CH3Si), 0.55 (6H, q, J=7.8 Hz, 3 ×SiCH2), 0.89 [9H, s, (CH3)3C], 0.93(3H, d, J=6.8 Hz, CH3CH), 0.94 (9H, t, J=7.8 Hz, 3 ×SiCH2CH3), 2.27 (2H, m, CH2CH═), 2.42 (1H, m, CH—CH3), 3.59 (2H, m, OCH2), 5.20 (dd, J=10.8, 9.7 Hz, ═CH—CHCH3), 5.29 (1H, dt, J=10.8, 7.4 Hz, CH2CH═CH); 13C NMR (125 MHz) δ−5.28 [SiCH3], 6.75 (SiCH2), 7.10 (CH3CH2Si), 18.37 [SiC(CH3)3], 21.29 [SiC(CH3)3], 22.32(CH2—CH2—CH2), 25.95 (CH—CH3), 29.80 and 29.89 [C(CH3) 2], 31.41 (CH2CH═), 31.90 (CH—CH3), 38.06 (CH—CH2—CH2), 45.20 (CH2CO), 63.23 (CH2O), 73.23 [C(CH3)2], 123.82 (CH2—CH═), 138.34 (═CHCH); MS (ES) 451 (M++Na); HRMS (ES) exact mass calculated for C24H52O2Si2Na (M++Na) 451.3404, measured 451.3414.
K. Hydrolysis of Silyl Protecting Groups in Diether 12 (Scheme 3)
To a stirred solution of compound 12 (201 mg, 0.4 mmol) in anhydrous CH2Cl2 (10 mL) was added hydrofluoric acid (48%, 6 mL). After 40 minutes of stirring at room temperature, water was added, and the organic layer was separated, washed with water and NaHCO3, dried over MgSO4, and evaporated. The residue was chromatographed on silica Sep-Pak cartridge using hexane/EtOAc (6:4) as an eluent to give an oily diol 13 (76.4 mg, 92%).
13: 1H NMR (500 Hz, CDCl3) δ0.95 (3H, d, J=6.7 Hz, CH3CH), 1.19 and 1.20 [3H and 3H, each s, C(CH3)2], 2.33 (2H, m, CH2CH═), 2.48 (1H, br m, CH—CH3), 3.64 (2H, t, J=6.4 Hz, CH2OH), 5.31 (2H, m, CH═CH); 13C NMR (50 MHz) δ21.63 (CH—CH3), 22.26 (CH2—CH2—CH2), 29.25 and 29.60 [C(CH3)3], 31.27 (CH2CH═), 31.87 (CH—CH3), 37.96 (CH—CH2—CH2), 44.00 (CH2CO), 62.55 (CH2OH), 71.29 [C(CH3)2], 124.09 (CH2—CH═), 139.70 (═CHCH).
L. Hydrogenation of Unsaturated Diol 13
To a solution of diol 13 (55 mg, 0.27 mmol) in ethyl acetate (10 mL) was added Pd/C (10%, 50 mg). The reaction mixture was stirred for 18 hours under a continuous stream of hydrogen at room temperature. The mixture was then filtered, and the solvent was evaporated under reduced pressure. The crude oily product was chromatographed on silica Sep-Pak cartridge eluted with hexane/EtOAc (8:2) to give an oily diol 14 (55 mg, 45%).
14: [α]24D −5.9° (c 0.27, CHCl3), 1H NMR (200 Hz, CDCl3) δ0.87 (3H, d, J=6.4 Hz, CH—CH3), 1.21 [6H, s, C(CH3)2], 1.56 (1H, br m, CH—CH3), 3.64(2H, t, j=6.4 Hz, CH2OH); 13C NMR (50 MHz) δ19.61 (CH—H3), 21.75 (CH2), 23.22 (CH2), 29.24 and 29.29 [C(CH3)3], 32.75 (CH—CH3), 33.10 (CH2), 36.76 (CH2), 37.48(CH2), 44.22 (CH2CO), 63.07 (CH2OH), 71.11 [C(CH3)2]; MS (ES) 225 (M++Na); HRMS (ES) exact mass calculated for C12H24O2Na (M++Na) 225.1831, measured 225.1823.
M. Oxidation of Diol 14
To a stirred solution of diol 14 (25 mg, 0.12 mmol) in anhydrous CH2Cl2 (3.5 mL) was added Dess-Martin reagent (73 mg, 0.15 mmol) at room temperature. The reaction was stirred at room temperature for 1.5 hours. Then, an aqueous solution of sodium thiosulfate (6 mL) and saturated NaHCO3 (6 mL) were added. The reaction was extracted with CH2Cl2, solvents were removed under reduced pressure, and the crude oil was purified on silica Sep-Pak using hexane/EtOAc (7:3) as an eluent to give an oily aldehyde 15 (16.5 mg, 67%).
15:1H NMR (200 Hz, CDCl3) δ0.88 (3H, d, J=6.4 Hz, CH—CH3), 1.21 [6H, s, C(CH3)2], 2.41 (2H, dt, J=1.7, 7.3 Hz, CHCHO), 9.77 (1H, t, J=1.7 Hz, CHO).
N. Silylation of Hydroxy Aldehyde 15
To a solution of aldehyde 15 (16.5 mg, 82.5 μmol) and 2,6-lutidine (24 μL, 206 ,μmol) in anhydrous CH2Cl2 (1.1 mL) was added dropwise Et3SiOTf (42 μL, 165 μmol) at −78° C. The mixture was stirred for 2 hours at −78° C. and for one additional hour at −50° C. Water and CH2Cl2 were added, the organic layer was washed with water, dried over MgSO4, and evaporated. The residue was chromatographed on silica Sep-Pak cartridge using hexane/EtOAc (99.7:0.3) as an eluent to give oily aldehyde 16 (22 mg, 85%). An analytical sample was obtained using HPLC (10 mm ×25 cm Zorbax-Sil column, 4 mL/min) with a hexane/EtOAc (98:2) solvent system. Analytically pure aldehyde 16 was collected at Rv=33 mL.
16: 1H NMR (500 Hz, CDCl3) δ0.55 (6H, q, J=7.9 Hz, 3 ×SiCH2CH3), 0.88 (3H, d, J=6.4 Hz, CH—CH3), 0.94 (9H, t, J=7.9 Hz, 3 x SiCH2CH3), 1.19 [6H, s, C(CH3)2], 2.41 (2H, m, CH2CHO), 9.77 (1H, t, J=1.8 Hz, CHO).
O. Wittig-Horner Reaction of Aldehyde 16
To a solution of phosphine oxide 17 (45.7 mg, 78.5 μmol) in anhydrous THF (0.6 mL) at −78° C. was slowly added n-BuLi (51 μL, 81.8 μmol) under argon with stirring. The solution turned deep orange upon addition. The stirring was continued for 20 minutes at −78° C. and then a precooled solution of aldehyde 16 (22 mg, 70 μmol) in anhydrous THF (100 μL) was slowly added. The mixture was stirred for 3 hours at −78° C. and at 6° C. for 16 hours. EtOAc, saturated NaHCO3 and brine were then added to the reaction vessel. The organic layer was washed with water, dried, and evaporated under reduced pressure. The residue was dissolved in hexane and applied on silica Sep-Pak cartridge using hexane/EtOAc (99.8:0.2) as an eluent to give the crude protected vitamin 18. The product was then purified by HPLC (10 mm ×25 cm Zorbax-Sil column, 4 mL/min) using a hexane/EtOAc (99.9:0.1) solvent system. Analytically pure vitamin D compound 18 (21.2 mg, 45%) was collected at Rv=18 mL.
18: UV (hexane) λmax 235.0 (ε 15 900), 242.0 (ε 24 800), 250.0 (ε 22 600) nm; 1H NMR (500 Hz, CDCl3) δ0.04, 0.05, 0.07 and 0.08 (each 3H, each s, 4 ×SiCH3), 0.57 (6H, q, J=7.9 Hz, 3 ×SiCH2CH3), 0.86 (3H, d, J=7.4 Hz, CH—CH3), 0.87 and 0.90 [9H and 9H, each s, 2 ×(CH3)3CSi], 0.95 (9H, t, J=7.9 Hz, 3 ×SiCH2CH3), 1.19 [6H, s, C(CH3)2], 2.07 (2H, m, 4′-H2), 2.15 (1H, dd, j=12.5, 8.1 Hz), 2.35-2.5 (3H, br m), 4.43 (2H, m, 1- and 3-H), 4.94 and 4.95 (1 H and 1 H, each s, C═CH2); 5.63 (1H, dt, J=15.0, 6.9 Hz, 3′-H), 5.90 (1H, d, J=10.9 Hz, 1′-H), 6.24 (1H, dd, J=15.0, 10.9 Hz, 2′-H); MS (El) m/z (relative intensity) 678 (M+, 10), 649 (M+−Et, 5), 621 (M+−tBu, 12), 546 (12), 73 (100); HRMS (ESI) exact mass calculated for C39H78O3Si3 678.5259, measured 678.5272.
P. Removal of Protecting Groups of 18
To a stirred solution of 18 (21.2 mg, 31.2 μmol) in anhydrous THF (3 mL) was added tetrabutylammonium fluoride (1 M in THF, 370 μL, 0.37 mmol). The resulting mixture was stirred for 18 hours at room temperature. Solvent was removed in vacuo, and the residue was dissolved in hexane/EtOAc (9:1) and applied on silica Sep-Pak. Elution with hexane/EtOAc (1:1) provided crude product 19. The vitamin was further purified by HPLC (10 mm ×25 cm Zorbax-Sil column, 4 mL/min) using a hexane/2-propanol (8:2) solvent system. Analytically pure vitamin D compound 19 (6.9 mg, 66%) was collected at Rv=21 mL.
19: UV (hexane) λmax 234.0 (ε27 800), 241.0 (ε30 200), 248.5 (sh, ε19 900) nm; 1H NMR (400 Hz, CDCl3) δ0.86 (3H, d, J=6.5 Hz, CH—CH3), 1.21 [6H, s, C(CH3)2], 2.08 (2H, q, J=6.9 Hz, 4′-H2), 2.26 (1H, dd, J=13.1, 7.1 Hz), 2.39(1H, dd, J=13.4, 7.2 Hz), 2.56 (1H, dd, J=13.5, 4.2 Hz), 2.70 (1H, dd, J=13.3, 4.3 Hz), 4.48 (2H, m, 1- and 3-H), 5.10 (2H, s, C═CH2); 5.70 (1H, dt, J=15.0, 6.9 Hz, 3′-H 6.03 (1H, d, J=10.8 Hz, 1′-H), 6.29 (1H, dd, J=15.0, 10.8 Hz, 2′-H); MS (El) m/z (relative intensity) no M+, 318 (M+−H2O, 19), 300 (8), 285 (4), 59 (100); HRMS (ESI) exact mass calculated for C2H34O2 (M+−H2O) 318.2559, measured 318.2570.
Test Material
Protein Source
Full-length recombinant rat receptor was expressed in E. coli BL21 (DE3) Codon Plus RIL cells and purified to homogeneity using two different column chromatography systems. The first system was a nickel affinity resin that utilizes the C-terminal histidine tag on this protein. The protein that eluted from this resin was further purified using ion exchange chromatography (S-Sepharose Fast Flow). Aliquots of the purified protein were quick frozen in liquid nitrogen and stored at −80° C. until use. For use in binding assays, the protein was diluted in TEDK50 (50 mM Tris, 1.5 mM EDTA, pH 7.4, 5 mM DTT, 150 mM KCI) with 0.1% Chaps detergent. The receptor protein and ligand concentration was optimized such that no more than 20% of the added radiolabeled ligand is bound to the receptor.
Study Druqs
Unlabeled ligands were dissolved in ethanol and the concentrations were determined using UV spectrophotometry (1,25(OH)2D3: molar extinction coefficient=18,200 and λmax=265 nm). Radiolabeled ligand (3H-1,25(OH)2D3, ˜159 Ci/mmol) was added in ethanol at a final concentration of 1 nM.
Assay Conditions
Radiolabeled and unlabeled ligands were added to 100 mcl of the diluted protein at a final ethanol concentration of ≦10%, mixed and incubated overnight on ice to reach binding equilibrium. The following day, 100 mcl of hydroxylapatite slurry (50%) was added to each tube and was mixed at 10-minute intervals for 30 minutes. The hydroxylapaptite was collected by centrifugation and was then washed three times with Tris-EDTA buffer (50 mM Tris, 1.5 mM EDTA, pH 7.4) containing 0.5% Titron X-100. After the final wash, the pellets were transferred to scintillation vials containing 4 mL of Biosafe II scintillation cocktail, mixed and placed in a scintillation counter. Total binding was determined from the tubes containing only radiolabeled ligand.
Test Material
Study Drugs
The study drugs were dissolved in ethanol and the concentrations determined using UV spectrophotometry. Serial dilutions were prepared so that a range of drug concentrations was tested without changing the final concentration of ethanol (≦0.2%) present in the cell cultures.
Cells
Human promyelocytic leukemia (HL60) cells were grown in RPMI-1640 medium containing 10% fetal bovine serum. The cells were incubated at 37° C. in the presence of 5% CO2.
Assay Conditions
HL60 cells were plated at 1.2 x 105cells/mL. Eighteen hours after plating, cells in duplicate were treated with drug. Four days later, the cells were harvested and a nitro blue tetrazolium reduction assay was performed (Collins et al., 1979; J. Exp. Med. 149:969-974). The percentage of differentiated cells was determined by counting a total of 200 cells and recording the number that contain intracellular black-blue formazan deposits. Verification of differentiation to monocytic cells was determined by measuring phagocytic activity.
Transcription activity was measured in ROS 17/2.8 (bone) cells that were stably transfected with a 24-hydroxylase (240hase) gene promoter upstream of a luciferase reporter gene (Arbour et al., 1998). Cells were given a range of doses. Sixteen hours after dosing the cells were harvested and luciferase activities were measured using a luminometer. RLU=relative luciferase units.
Antagonism was tested by adding a combination of 1,25(OH)2D3 and the compound in the same well keeping the final ethanol concentration the same.
Male, weanling Sprague-Dawley rats were placed on Diet 11 (Suda et al. J. Nutr. 100:1049, 1970) (0.47% Ca) diet +vitamins AEK for one week followed by Diet 11 (0.02% Ca) +AEK for 3 weeks. The rats were then switched to a diet containing 0.47% Ca for one week followed by two weeks on a diet containing 0.02% Ca. Dose administration began during the last week on 0.02% calcium diet. Four consecutive ip doses were given approximately 24 hours apart. Twenty-four hours after the last dose, blood was collected from the severed neck and the concentration of serum calcium was determined as a measure of bone calcium mobilization. The first 10 cm of the intestine was also collected for intestinal calcium transport analysis using the everted gut sac method. Antagonism was tested by administering a combination of 1,25(OH)2D3 and the compound to the animal simultaneously.
The compounds of the invention were prepared and studied using the methods described above. The compounds were/are found to exhibit desired, and highly advantageous, patterns of biological activity with respect to intestinal calcium transport activity, ability to mobilize calcium from bone, and ability to bind to the vitamin D receptor. The compounds are also found to moderate cell differentiation activity.
The compound of formula 1C4 (Des-C,D) does not bind to the vitamin D receptor as strongly as the native hormone 1,25-(OH)2D3 as shown in
For treatment purposes, the compounds of the invention may be formulated for pharmaceutical applications as a solution in innocuous solvents, or as an emulsion, suspension or dispersion in suitable solvents or carriers, or as pills, tablets or capsules, together with solid carriers, according to conventional methods known in the art. Any such formulations may also contain other pharmaceutically acceptable and non-toxic excipients such as stabilizers, anti-oxidants, binders, coloring agents or emulsifying or taste-modifying agents. Pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in “Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is hereby incorporated by reference in its entirety and for all purposes as if fully set forth herein.
The compounds may be administered orally, topically, parenterally, rectally, or transdermally. The compounds are advantageously administered by injection or by intravenous infusion or suitable sterile solutions, or in the form of liquid or solid doses via the alimentary canal, or in the form of creams, ointments, patches, or similar vehicles suitable for transdermal applications. In some embodiments, doses of from 0.001 μg to about 1 mg per day of the compound are appropriate for treatment purposes. In some such embodiments an appropriate and effective dose may range from 0.01 μg to 1 mg per day of the compound. In other such embodiments an appropriate and effective dose may range from 0.1 μg to 500 μg per day of the compound. Such doses will be adjusted according to the type of disease or condition to be treated, the severity of the disease or condition, and the response of the subject as is well understood in the art. The compound may be suitably administered alone, or together with another active vitamin D compound.
Compositions for use in the invention include an effective amount of a compound of any of the embodiments as the active ingredient or ingredients, and a suitable carrier. An effective amount of the compound or compounds for use in accordance with some embodiments of the invention will generally be a dosage amount such as those described herein, and may be administered topically, transdermally, orally, nasally, rectally, or parenterally.
Dosages as described above are suitable, it being understood that the amounts given are to be adjusted in accordance with the severity of the disease, and the condition and response of the subject as is well understood in the art. As noted, the compounds of the invention may be present as a mixture of two or more compounds. In some mixtures, the mixture may include a first compound of the invention and a second compound of the invention. In some embodiments, the mixture includes the first compound and the second compound, and the ratio of the first compound to the second compound ranges from 50:50 to 99.9:0.1. In some such embodiments, the ratio of the first compound to the second compound ranges from 70:30 to 99.9:0.1, from 80:20 to 99.9:0.1, from 90:10 to 99.9:0.1, or from 95:5 to 99.9:0.1.
The compound or compounds may be formulated as creams, lotions, ointments, aerosols, suppositories, topical patches, pills, capsules or tablets, or in liquid form as solutions, emulsions, dispersions, or suspensions in pharmaceutically innocuous and acceptable solvent or oils, and such preparations may contain, in addition, other pharmaceutically innocuous or beneficial components, such as stabilizers, antioxidants, emulsifiers, coloring agents, binders or taste-modifying agents.
The formulations of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredients. The carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.
Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.
Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and carrier such as cocoa butter, or in the form of an enema.
Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.
Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops; or as sprays.
For nasal administration, inhalation of powder, self-propelling or spray formulations, dispensed with a spray can, a nebulizer or an atomizer can be used. The formulations, when dispensed, preferably have a particle size in the range of 10 to 100 microns.
The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. By the term “dosage unit” is meant a unitary, i.e., a single dose which is capable of being administered to a patient as a physically and chemically stable unit dose comprising either the active ingredient as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
All references cited herein are specifically incorporated by reference in their entireties and for all purposes as if fully set forth herein.
It is understood that the invention is not limited to the embodiments set forth herein for illustration, but embraces all such forms thereof as come within the scope of the following claims.
This application claims priority to U.S. Provisional Application No. 60/712,365, filed Aug. 30, 2005, the entire contents of which are incorporated by reference herein and for all purposes as if fully set forth herein.
| Number | Date | Country | |
|---|---|---|---|
| 60712365 | Aug 2005 | US |
